Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability

This publication has 33 references indexed in Scilit:

• Site-specific PEGylation of native disulfide bonds in therapeutic proteins
  Nature Chemical Biology, 2006
• Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7–37)/polymer conjugate to isolated rat islets
  Biomaterials, 2005
• Site-specific PEGylation of proteins containing unnatural amino acids
  Bioorganic & Medicinal Chemistry Letters, 2004
• Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency
  Biochemical and Biophysical Research Communications, 2004
• Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1
  Drug Development Research, 2001
• Biological Activities of Glucagon-Like Peptide-1 Analogues in Vitro and in Vivo
  Biochemistry, 2001
• Bioconjugation of Tumor Necrosis Factor-α with the Copolymer of Divinyl Ether and Maleic Anhydride Increasing Its Antitumor Potency
  Biochemical and Biophysical Research Communications, 1997
• The Positive Charge of the Imidazole Side Chain of Histidine7 Is Crucial for GLP-1 Action.
  Endocrine Journal, 1997
• A role for glucagon-like peptide-1 in the central regulation of feeding
  Nature, 1996
• Pegylated peptides IV
  International Journal of Peptide and Protein Research, 1995